Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...

Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...

Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...